ABBI Abraxis Bioscience (MM)

Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today announced that its hospital-based products business, Abraxis Pharmaceutical Products (APP), has launched Doxorubicin Hydrochloride Injection, USP 2mg/mL, the generic equivalent of Adriamycin� PFS which is owned by Bedford Laboratories, a division of Boehringer Ingelheim GmbH. According to IMS, sales in 2006 of doxorubicin hydrochloride injection in the United States exceeded $30 million. Contracts for this product have already been secured and APP expects to immediately commence marketing of Doxorubicin, which is commonly used in the treatment of a wide range of cancers. The product is AP rated, preservative-free and latex-free. Doxorubicin has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms� tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin�s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of auxiliary lymph node involvement following resection of primary breast cancer. About Abraxis BioScience, Inc. Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab� platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE�, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the Nasdaq Global Market under the symbol ABBI. For more information about the company and its products, please visit www.abraxisbio.com. Adriamycin� is a registered trademark of Bedford Laboratories, a division of Boehringer Ingelheim GmbH